Say hello to MassDevice +3, a bite-sized view of the top three medtech stories of the day. This feature of MassDevice.com's coverage highlights our 3 biggest and most influential stories from the day's news to make sure you're up to date on the headlines that continue to shape the medical device industry.
FDA clarifies existing stance on acceptance of medical device clinical data from studies conducted outside the United States.
Sen. Richard Burr (R-N.C.) introduces a new bill to create fast-track approvals at the FDA for breakthrough medical devices.
A new Senate bill introduced yesterday would create a fast-track program at the FDA for breakthrough medical devices
The bill, S. 1077 or " A bill to provide for expedited development of and priority review for breakthrough devices," was sponsored by Sen. Richard Burr (R-N.C.) and co-sponsored by Sens. Orrin Hatch (R-Utah) and Michael Bennet (D-Colo.).
Spectranetics says it plans to boost its R&D spend on the Stellarex drug-eluting balloon it bought from Covidien.
Gynesonics pulls in $3 million in a new debt financing that will help fuel further development of its VizAblate fibroid treatment device.
California's Gynesonics reported raising $3 million in a new debt offering as it pursues development of its VizAblate fibroid treatment device.
Share prices tick up for C.R. Bard after it reports a 1st-quarter earnings beat.
C.R. Bard (NYSE:BCR) shares gained today after the medical products giant reported 1st-quarter earnings that topped expectations on Wall Street, despite a poor quarterly comparison for its Lutonix drug-eluting balloon.
Halloran expands clinical finance services and licenses leading industry financial forecasting tool to effectively budget and manage clinical trial budgets.
BOSTON, MA – Halloran Consulting Group, the life science management consulting firm, expands its robust range of clinical finance capabilities with the addition of the industry's leading financial forecasting tool.
